Volume 124, Issue 4 , Pages 745-750.e4, October 2009
Cats and dogs and the risk of atopy in childhood and adulthood
Background
Exposure to cats and dogs during childhood has been linked to a lower risk of developing allergies. It remains unclear whether this is due to selective avoidance of pets by families with a history of allergies. The effects of pet ownership in adulthood are unknown.
Objectives
We sought to assess the association between cat and dog ownership in childhood and early adulthood and the development of atopy in a population-based birth cohort of 1037 subjects.
Methods
Ownership of cats or dogs between birth and age 9 years and between the ages of 18 and 32 years was reported. Skin prick tests to common allergens were performed at 13 and 32 years.
Results
There was no evidence that families with a history of atopy avoided owning pets. There were significant cat-by-dog interactions for the development of atopy in both childhood and adulthood. Children who had owned both a cat and a dog were less likely to be atopic at age 13 years. Living with only one of these animals was not protective against atopy. Among those who were not atopic by age 13 years, having both a cat and a dog in adulthood was associated with a lower risk of new atopy by age 32 years. This association was only significant among those with a parental history of atopy. These effects were independent of a range of potential confounding factors.
Conclusions
There is a synergistic interaction between cat and dog exposure that is associated with a lower risk of developing atopy in childhood and young adulthood.
Key words: Animals, pets, risk factors, cat, dog, atopy, interaction
Abbreviation used: OR, Odds ratio
The Dunedin Multidisciplinary Health and Development Research Unit is funded by the Health Research Council of New Zealand. P. J. M. was a CIHR Strategic Training Fellow in the Canadian Child Health Clinician Scientist Program (CCHCSP).W. Y. W. L. holds a Canada Research Chair in Statistical Methods for Health Care. M. R. S. holds the AstraZeneca Chair in Respiratory Epidemiology, McMaster University.
Disclosure of potential conflict of interest: P. J. Mandhane has received honoraria from AstraZeneca Canada, Merck Frosst Canada, and the Edmonton Thoracic Society and has received research support from AstraZeneca Canada and Merck Frosst Canada. R. Poulton has received research support from the Health Research Council (New Zealand). R. J. Hancox has received research support from the Health Research Council (New Zealand). The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(09)00994-4
doi:10.1016/j.jaci.2009.06.038
© 2009 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 124, Issue 4 , Pages 745-750.e4, October 2009
